



## MEDICAL TIPS

### DIABIZ TABLETS

Issue VII, No. 27, 2022

#### **Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials**

Wu QL et al. *Diabetology & Metabolic Syndrome* 2022; 14(41).

- Preclinical studies have demonstrated the atherogenic potential of dapagliflozin, a selective SGLT2 inhibitor.
- In order to confirm this hypothesis, pooled data from 12RCTs (18,758 patients) was incorporated in the current meta-analysis.
- Dapagliflozin was associated with a significant increase in HDL-C levels, flow mediated vasodilation and the eGFR.
- Furthermore, dapagliflozin had a tremendous advantage in controlling the TG levels, SBP, HbA1c, BMI, body weight and waist circumference

**The above results summarize that dapagliflozin could be a therapeutic option for the progression of atherosclerosis in patients with T2DM.**

